This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study, Intestinal Research, September 2025, Korean Association for the Study of Intestinal Diseases (KAMJE),
DOI: 10.5217/ir.2025.00067.
You can read the full text:
The following have contributed to this page
